MX2020004678A - Uso de profarmacos de riluzol para tratar ataxias. - Google Patents

Uso de profarmacos de riluzol para tratar ataxias.

Info

Publication number
MX2020004678A
MX2020004678A MX2020004678A MX2020004678A MX2020004678A MX 2020004678 A MX2020004678 A MX 2020004678A MX 2020004678 A MX2020004678 A MX 2020004678A MX 2020004678 A MX2020004678 A MX 2020004678A MX 2020004678 A MX2020004678 A MX 2020004678A
Authority
MX
Mexico
Prior art keywords
ataxias
treat
riluzole
riluzole prodrugs
prodrugs
Prior art date
Application number
MX2020004678A
Other languages
English (en)
Inventor
Vladimir Coric
Robert Berman
Melissa Beiner
Gilbert L''ITALIEN
Original Assignee
Biohaven Pharm Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharm Holding Co Ltd filed Critical Biohaven Pharm Holding Co Ltd
Publication of MX2020004678A publication Critical patent/MX2020004678A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con métodos para el tratamiento de ataxia, administrando a un paciente en necesidad del mismo, un profármaco de riluzol, tal como troriluzol. También se describen composiciones farmacéuticas y kits que incluyen los profármacos de riluzol.
MX2020004678A 2017-11-12 2018-11-11 Uso de profarmacos de riluzol para tratar ataxias. MX2020004678A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762584856P 2017-11-12 2017-11-12
US201862717948P 2018-08-13 2018-08-13
PCT/US2018/060232 WO2019094851A1 (en) 2017-11-12 2018-11-11 Use of riluzole prodrugs to treat ataxias

Publications (1)

Publication Number Publication Date
MX2020004678A true MX2020004678A (es) 2020-08-13

Family

ID=66438598

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020004678A MX2020004678A (es) 2017-11-12 2018-11-11 Uso de profarmacos de riluzol para tratar ataxias.
MX2023012640A MX2023012640A (es) 2017-11-12 2020-07-13 Uso de profarmacos de riluzol para tratar ataxias.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023012640A MX2023012640A (es) 2017-11-12 2020-07-13 Uso de profarmacos de riluzol para tratar ataxias.

Country Status (13)

Country Link
US (3) US20210023061A1 (es)
EP (1) EP3706739B1 (es)
JP (2) JP7352542B2 (es)
KR (1) KR20200103658A (es)
CN (1) CN112292127A (es)
AU (1) AU2018364749C1 (es)
BR (1) BR112020009173A2 (es)
CA (1) CA3082096A1 (es)
IL (1) IL274532B2 (es)
MX (2) MX2020004678A (es)
PH (1) PH12020550583A1 (es)
SG (1) SG11202004332XA (es)
WO (1) WO2019094851A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034759B1 (ru) 2015-03-03 2020-03-17 Биохэйвен Фармасьютикал Холдинг Компани Лтд. Пролекарства рилузола и их применение
WO2018031707A1 (en) 2016-08-10 2018-02-15 Biohaven Pharmaceutical Holding Company Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
WO2022155564A1 (en) * 2021-01-18 2022-07-21 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
WO2023081859A1 (en) * 2021-11-04 2023-05-11 Skyhawk Therapeutics, Inc. Triazine amino derivatives for treating sca3
WO2023230451A2 (en) * 2022-05-23 2023-11-30 Biohaven Therapeutics Ltd. Methods of treating spinocerebellar ataxias

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU691195B2 (en) 1993-07-09 1998-05-14 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US5457895A (en) 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
US5837287A (en) 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
ATE421318T1 (de) 1997-02-20 2009-02-15 Massachusetts Inst Technology Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben
PT1001748E (pt) 1997-07-25 2006-08-31 Alpex Pharma Sa Um processo para a preparacao de um granulado adequado para a preparacao de comprimidos rapidamente desintegraveis na boca
JP4809533B2 (ja) 1998-11-20 2011-11-09 オバン・エナジー・リミテッド 分散し得るリン脂質で安定化されたミクロ粒子
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
ATE371442T1 (de) 2001-10-12 2007-09-15 Elan Pharma Int Ltd Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
CN100556762C (zh) 2002-02-13 2009-11-04 迈克尔K·韦伯尔 药物剂型及其制造方法
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
BRPI0620578A2 (pt) 2005-12-27 2011-12-06 Jubilant Organosys Ltd composição farmacêutica que dissolve na boca e processo para o preparo da mesma
WO2009002084A2 (en) 2007-06-27 2008-12-31 Hanmi Pharm. Co., Ltd. Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same
WO2009146031A1 (en) * 2008-03-31 2009-12-03 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
US8518031B2 (en) 2008-10-31 2013-08-27 The Invention Science Fund I, Llc Systems, devices and methods for making or administering frozen particles
US8603496B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
EA034759B1 (ru) * 2015-03-03 2020-03-17 Биохэйвен Фармасьютикал Холдинг Компани Лтд. Пролекарства рилузола и их применение

Also Published As

Publication number Publication date
US20210023061A1 (en) 2021-01-28
IL274532B2 (en) 2024-05-01
JP2023175823A (ja) 2023-12-12
KR20200103658A (ko) 2020-09-02
JP7352542B2 (ja) 2023-09-28
MX2023012640A (es) 2023-11-08
EP3706739A1 (en) 2020-09-16
US20230390252A1 (en) 2023-12-07
US12102618B2 (en) 2024-10-01
EP3706739B1 (en) 2024-10-16
CN112292127A (zh) 2021-01-29
AU2018364749A1 (en) 2020-07-02
BR112020009173A2 (pt) 2020-11-03
WO2019094851A1 (en) 2019-05-16
AU2018364749B2 (en) 2023-11-09
EP3706739A4 (en) 2021-08-04
CA3082096A1 (en) 2019-05-16
IL274532A (en) 2020-06-30
SG11202004332XA (en) 2020-06-29
PH12020550583A1 (en) 2021-05-31
IL274532B1 (en) 2024-01-01
AU2018364749C1 (en) 2024-02-15
US20230355592A1 (en) 2023-11-09
NZ765220A (en) 2023-11-24
JP2021502392A (ja) 2021-01-28

Similar Documents

Publication Publication Date Title
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
MX2020004678A (es) Uso de profarmacos de riluzol para tratar ataxias.
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
UY37272A (es) Piridinas sustituidas con heteroarilo y métodos de uso
DOP2016000194A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
CL2017000521A1 (es) Inhibidores de desmetilasa-1 específica a lisina
PH12017500746B1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
UY35916A (es) Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio
BR112016023558A2 (pt) compostos úteis como imunomoduladores
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
NI201700056A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer
CL2016002346A1 (es) Composiciones para modular la expresión de ataxina 2
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
UY36702A (es) Piridinas sustituidas y métodos de uso
BR112019021867A2 (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil
UY36677A (es) Compuestos tricíclicos como agentes antineoplásicos
DOP2017000107A (es) Diamino-quinoleina 2,4 sustituida como nuevos agentes anticancerigenos
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
CR20160600A (es) Quinolizione derivados como inhibidores pi3k
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CL2021000329A1 (es) Compuestos útiles en terapia del vih
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
DOP2018000011A (es) Sales y profármacos de 1-metil-d-triptófano